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‘Peripheral’ binding sites for henzodiazepines areunder neural or homonal control in the pineal gland, olfac- 
tory butb, and kidney. These observations prompted a search for an endogenous substance which could 
modulate these sites under physiological conditions. Acidified methanol extracts from several tissues (e.g. 
stomach, kidney, lung) were found to inhibit the binding of [311jRo 5-4864 to ‘peripheral’ binding sites, but 
did not signifleantly affect he binding of [3H]diazepam to ‘brain’ henzodiazepine receptors. Fractionation 
of a crude extract prepared from antral stomach by either ultrafiltration or gel filtration chromatography 
yielded high .(&.fr > 10000) and low (M, < 1000) M, fractions which competitively inhibited [jFIjRo 5-4864 
binding to ‘peripheral’ sites. These observations suggest the presence of endogenous substances in several 
rat tissues which may represent physiologically important ligands for ‘peripheral’ binding sites for henzo- 
diazepines. 
Berxzodiazepine receptor 5-4864 Antral stomach Kidney Diazepam 4-Chiorodiazepam (R5 56864) 
1. ~NTRO~U~ION 
The demonstration that psychopharmacologic- 
ally active beuzodiazepines bind to unique recogui- 
tion sites (receptors) in the rn~rn~~ central ner- 
vous system [1,2] prompted a search for endoge- 
nous ligaud(s) which could physiologically sub- 
serve these sites. Proteins, peptides, purine, indole 
derivatives and lipids which inhibit f3H]diazepam 
or [3H]flunitrazepam binding to brain membranes 
have been identified [3-51. Such substances appear 
to interact with ‘brain’ benzodiazepine receptors 
[6,7], but not with binding sites for benzodiazep- 
ines which were first described in peripheral tissues 
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[8,9], tr~sform~ cells of neural origin flO] and 
more recently in the central nervous system [1 11. 
While the physiological and pharmacological 
importance of ‘brain’ benzodiazepine receptors is 
generally acknowl~g~ 1121, the biological relev- 
ance of ‘peripheral’ binding sites for benzodiaze- 
pines (PBS) is unknown. Recently, we have found 
that lateral olfactory tract lesions decrease the den- 
sity of PBS in olfactory bulb, and that PBS in 
pineal gland are under neural control [13,14]. 
Others have shown that destruction of the olfac- 
tory nerve with ZnSO4 decreases the density of 
PBS binding in the olfactory bulb 1151. Moreover, 
PBS in kidney have also been shown to be altered 
in several animal models of hypertension [16-181, 
further supporting the presence of a neural and 
hormonal regulation of these sites. These observa- 
tions stimulated a search for an endogenous 
substance which could physiologically regulate 
PBS. 
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We now report the presence of high (M,> 
10000) and low (M,c 1000) mr substances isolated 
from rat tissues which selectively inhibit the bin- 
ding of t31-I]Ro 5-4864 to PBS in a competitive 
fashion. There is more than a 50-f&d variation in 
the concentration of these substances in the tissues 
examined. These results suggest that endogenous 
substances present in the rat may physiologically 
regulate PBS. 
2. MATERIALS AND METHODS 
2.1. Extraction and isolation procedures 
Male Sprague-Dawley rats (Taconic Farms, 
Germantown, NY) (200-225 g) were killed by 
decapitation and the tissues removed and quickly 
frozen on solid COz. When appropriate, fat and 
connective tissue were removed prior to freezing. 
The tissue was weighed and allowed to thaw in 3 
vol. of cold acidified methanol (20~1 glacial acetic 
acid/ 100 ml methanol). Tissues were minced and 
homogenized for 30 s with a Polytron (setting 7-8) 
~rinkma~ I~st~me~ts, Westbury, NY). The 
resulting homogenates were centrifuged at 20000 
x g for 20 min (4’C). The su~rnatants were 
transferred to 50 ml vacuum flasks, and the sample 
volume reduced under vacuum at room tempera- 
ture until the volume was reduced to the approx- 
imate original tissue weight. Samples were then 
heated for 15 min (55%) and centrifuged at 40000 
x g for 30 min (4OC). The resulting supernatant 
was transferred to test tubes, frozen on solid CO2 
and lyophilized. The lyophilized residue was then 
reconstituted in 10% of the original volume with 
cold distilled water (this material is referred to as 
the ‘crude extract’). The crude extract was filtered 
through an Amicon PM-10 filter (Amicon Corp., 
Danvers, MA), and the resulting filtrate passed 
through an Amicon UM-05 filter. Alte~atively, 
the crude extract was applied to a Bio8el P2 col- 
umn, and eluted with sodium phosphate buffer (20 
mM, pH 7.4) (fig.l). 
The amount of inhibitor present in the various 
tissue preparations was expressed as ‘units’ of in- 
hibitory activity. One ~in~bitory unit’ was equal to 
that concentration of Ro 5-4864 which inhibited 
the binding of [jH]Ro 5-4864 (1 nM) to rat cerebral 
cortical membranes by 50% (ICso). Under stan- 
dard incubation conditions, 0.25 nM (0.25 pmol/ 
assay) of Ro 5-4864 usually produced a 50% in- 
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Fig. 1. Flow scheme for partial puri~cation of en- 
dogenous substances inhibiting 13H]Ro J-4864 binding 
to PBS. 
hibition. Inhibition of f3HfRo S-4864 due to the 
presence of endogenous ubstances was trans- 
formed into the appropriate concentration of Ro 
5-4864 from the standard curve, and divided by the 
K’SO concentration to yield units of activity. 
2.2. Assuy of [s%l]benzodiiazepine bi ding 
The binding of [3H]diazepam to ‘brain’ beu- 
zodiazepine receptors and [‘H]Ro 5-4864 binding 
to PBS was d~e~ned as in [19]. In brief, rat 
cerebral cortex was homogenized in 100 vol. of 50 
mM Tris-HCl buffer (pH 7.4) and centrifuged at 
20008 x g for 20 min (4°C). Tissue was re- 
suspended in 100 vol. of the same buffer. Replicate 
tubes contained 0.6 ml of this tissue suspension, 
0.1 ml radioligand, and O-l-O.3 ml of drug, buffer, 
or column fraction. The reaction was initiated by 
addition of tissue and terminated after 60 min 
(0-4°C) by rapid filtration through Whatman 
OF/B filter strips using a Brandel M-24R Cell 
Harvester (Brandef Instruments, G~thersburg~ 
MD). Filters were washed twice with 5 ml of ice 
Volume 176, number 1 FEBS LETTERS October 1984 
cold buffer. The filters were suspended in 8 ml 
Ready-Solv MP (Beckman Instrument Co., Fuller- 
ton, CA), and the radioactivity measured in a 
Packard B-2450 liquid scintillation spectrometer. 
PK 11195 and Ro 15-1788 were used to determine 
the nonspecific binding of [3H]Ro 5-4864 and 
[3H]diazepam, respectively. 
2.3. Materials 
Radioactive ligands were purchased from New 
England Nuclear, Boston, MA. Benzodiazepines 
were donated by Dr Peter Sorter, Hoffmann-La 
Roche, Nutley, NJ. PK 11195 was the gift of Dr 
Gerard Le Fur, Pharmuka Co., Gennevilliers, 
France. Other chemicals were obtained from stan- 
dard commercial sources. 
3. RESULTS AND DISCUSSION 
Acidified methanol extracts of several tissues 
were far more potent inhibitors of t3H]Ro 5-4864 
(4’-chlorodiazepam) binding than [3H]diazepam 
binding to rat cortical membranes (fig.2). The 
specificity of the tissue extracts for these two close- 
ly related radioligands strongly suggests a selectivi- 
ty for PBS. These tissue extracts also inhibited 
[3H]Ro 5-4864 binding to kidney membranes (not 
shown), which suggests that the inhibitory action 
of these extracts is independent of the source of 
PBS. 
If endogenous inhibitors of [3H]Ro 5-4864 bind- 
ing are physiologically important, then an uneven 
distribution of these substances in various tissues 
might be predicted. We examined the tissue 
distribution of this factor(s) by measuring the 
amount of inhibitor present in crude extracts from 
several tissues (table 1). These experiments re- 
vealed more than a 50-fold difference in the con- 
centration of inhibitor present. Further, there ap- 
pears to be an inverse relationship between the 
concentration of inhibitor present and the density 
of PBS in each tissue (table l), suggesting that the 
density of PBS may be regulated by the amount of 
endogenous inhibitor present in the tissue. Alter- 
natively, endogenous inhibitors of PBS may be 
produced in one or more tissues and reach other 
organs via the circulation. The presence of in- 
hibitory activity in serum would seem to support 
the latter hypothesis, although both possibilities 
are currently under investigation. 
T 
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Fig. 2. Inhibition of [3H]benzodiaxepine binding by 
acidified methanol extracts from antral stomach. Ex- 
tracts were prepared as section 2 (see fig. 1). Aliquots of 
the nonlyophilixed extract were incubated for 60 min 
(4°C) with either 1 nM [‘H]Ro S-4864 (0) or 5 nM 
[3H]diaxepam (0) using rat cortical membranes as in 
section 2. Values are expressed as percent of specific 
binding relative to control incubations and represent he 
X+ SE for 3-6 independent experiments. 
When the crude extract (fig.1) was filtered 
through an Amicon PM-10 membrane (nominal 
molecular mass exclusion limit of 10 000 Da) about 
70% of the original activity was retained by the 
filter (table 2). The remaining activity was not re- 
tained by a UM-05 membrane (table 2) which has 
a nominal exclusion limit of 500 Da. The loss in ac- 
tivity following PM-10 filtration supports the no- 
tion that both high and low molecular mass in- 
hibitors are present in the crude extract. The filtra- 
tion membranes used in these experiments have 
been reported to adsorb both hydrophobic macro- 
molecules and steroids [20]. Since tissue extraction 
in methanol would favor the isolation of hydro- 
phobic substances, it is possible that a large quanti- 
ty of a low molecular mass species could have been 
bound to the PM-10 filter. However, a crude ex- 
tract prepared from rat antral stomach and chrom- 
atigraphically separated on a Biogel P2 column 
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Table 1 
Tissue distribution of endogenous inhibitors of PBS 
Tissue Inhibitor t3H]Ro 5-4864 bindinga 




















’ Comparative binding data were taken from [7] and 
[13] using [3H]Ro 5-4864 (1 nM) as radioligand 
b Serum activity is expressed as units/ml 
Tissues were homogenized in acidified methanol, cen- 
trifuged, and the supernatants concentrated under 
vacuum. Extracts were heated (SS’C), recentrifuged, 
and the second supernatant lyophilizecl as in section 2. 
Residues were reconstituted in 3 vol. of distilled water, 
and aliquots analyzed for inhibition of [3H]Ro 5-4864 
binding using rat cortical membranes a  a source of PBS 
Table 2 
Effect of ultrafiltration of acidified methanol extracts 
on inhibitory activity of a crude extract 
Preparation Activity Crude extract 
(units/ml) (Q) 
Crude extract 74 f 3.4 100 
PM-10 (Mr cut-off 104) 16 f 1.2 22 
Filtrate 
UM-05 @fr cut-off 500) 24 f 3.0 32 
Filtrate 
Frozen antral stomach tissue was homogenized in 
acidified methanol, centrifuged, and the supernatant 
volume reduced under vacuum as described in section 2. 
The extract was heated (SSOC), recentrifuged, and the se- 
cond supernatant lyophilized. The residue was recon- 
stituted in 3 volumes of water and sequentially passed 
through Amicon membrane filters. Aliquots were 
measured for inhibition of [3H]Ro 5-4864 binding at 
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Fig. 3. BioGel P2 column chromatography of rat antral 
stomach extracts. One milliliter of crude extract was ap- 
plied to a 2.5 x 50 cm Biogel P2 column which was 
eluted at a flow rate of 20 ml/h in 20 mM sodium 
phosphate buffer, pH 7.4. Five ml fractions were col- 
lected and 300 pl aliquots assayed for inhibition of 
[3H]Ro 5-4864 binding as in section 2., 
resulted in two discrete peaks of inhibitory activity 
(fig.3). Peak I eluted essentially with the void 
volume of this column, while a second fraction 
(Peak II) eluted with a retention time slightly 
greater than that of cyanocobalamin (M 1350). 
Thus, the results obtained by gel filtration are in 
agreement with data obtained using ultrafiltration, 
and suggest he presence of at least two factors 
which inhibit the binding of [3H]Ro 5-4864 to PBS. 
The sensitivity of these endogenous ubstances 
to proteolytic enzymes was then examined. The in- 
hibitory activity of a crude extract prepared from 
antral stomach (which contains both high and low 
molecular mass factors) was unaffected by extend- 
ed incubation iith pronase, a relatively nonselec- 
tive proteolytic enzyme (results not shown). The 
inability of pronase to affect the inhibitory activity 
present in the crude extract is striking, since that 
preparation contains the majority of inhibitory ac- 
tivity as a relatively high molecular mass substance 
as measured by both ultrafiltration and chromato- 
graphic techniques (table 2). If the inhibitory 
material is a peptide, the inability of pronase to 
alter the activity of the preparation suggests that 
either the cleaved fragments retain activity or that 
the amino acids are highly protected by other 
groups. It is presently not known if the high 
molecular mass inhibitor(s) is related to the lower 
molecular mass species. However, preliminary 
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Fig. 4. Inhibition of [-“H]Ro 5-4864 binding to PBS by 
BioGel P2 Peak II. Chromatographic fractions cor- 
responding to Peak II (see fig. 3) were lyophifized and 
reconstituted in 10% of their original volume with 
distilled water. The apparent affinity of [‘H]Ro 5-4864 
(KD = 0.73 nM, Bmax = 254 fmol/mg protein, w) 
was reduced in the presence of 50 pl (KD = 1.22 nM, 
B - 238 fmol/mg protein, 0-O) and 1OOltl (KD = max -
I.74 nM, 3,, = 234 fmollmg protein D-Cl) of in- 
hibitor. Peak I was also found to ~om~titively inhibit 
13H]Ro 54864 binding (not shown). Rat cerebral cortex 
was used to assay PBS. 
evidence with a Sephadex G-50 column suggests 
the molecular mass of the ‘high’ molecular mass 
species to be between 10000-15 000 Da (unpub- 
lished). 
Several lines of research also support the notion 
that an endogenous ligand(s) for PBS may be pre- 
sent in mammalian tissue. For example, 13H]Ro 
5-4864 binding in kidney membranes was noted to 
increase if the kidneys were perfused with saline 
prior to assay [ 1 l] which could remove or dilute an 
endogenous inhibitor. In other studies on the 
autoradiographic localization of r3H]PK III95 
binding to adrenal glands, kinetic analysis demon- 
strated that the affinity of this ligand for PBS was 
approximately lo-fold lower in adrenal slices than 
in homogenates [21]. Homogenization of this 
tissue may have also diluted an endogenous in- 
hibitor retained by slices [21]. Certainly, the com- 
petitive inhibition of [3H]Ro S-4864 binding to 
PBS by both Peaks I and II (fig.4) is consistent 
with a physiologic~ly relevant substance(s). 
The present studies have provided evidence that 
several tissues from the rat contain endogenous in- 
hibitors of PBS. Whether the substances character- 
ized here are identical with those reported to be 
present in human urine and plasma [22] is current- 
ly under investigation. Further purification and 
characterization of endogenous inhibitors of PBS 
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